MedTrace Logo

Dose Escalation Study for Primary Hepatocellular Carcinoma

NCT00243841 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2018-12-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the maximum tolerated dose of limited fractions of large dose radiation in an effort to achieve a biologically potent cancer therapy in selected patients with primary hepatocellular carcinoma.

Conditions

  • Carcinoma, Hepatocellular

Interventions

RADIATION

Stereotactic Body Radiation

Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • Indiana University School of Medicine

    lead OTHER

Principal Investigators

  • Mark Langer, MD · Indiana University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00243841 on ClinicalTrials.gov